Sobi Moves to Bolster Its Gout Pipeline With Arthrosi Deal
Sobi has entered into an agreement to acquire Arthrosi Therapeutics, a private late-stage biotechnology company focused on developing a new treatment option for gout.
The move is positioned as a strategic expansion of Sobi’s gout portfolio, adding a late-stage asset that could broaden the company’s reach beyond its established focus on rare disease therapies.
At the centre of the acquisition is pozdeutinurad (AR882), an investigational, once-daily oral urate transporter 1 (URAT1) inhibitor. The therapy is currently being evaluated in two global phase 3 studies, with results expected in 2026.
Its intended use is for the treatment of progressive and tophaceous gout – a more advanced form of the condition where urate crystal deposits (tophi) can form and contribute to ongoing inflammation, pain, and functional impairment.
Gout, widely recognised as the most common form of inflammatory arthritis, is driven by elevated levels of uric acid in the body. When uric acid accumulates around joints and other tissues, it can lead to sudden, painful flare-ups.
Over time, and particularly when left untreated, gout can progress beyond intermittent attacks into chronic disease, potentially causing lasting joint damage and a wider range of serious complications.
Financially, the agreement outlines a substantial commitment from Sobi. The company will pay $950 million in cash to acquire Arthrosi, alongside up to $550 million more in cash through clinical, regulatory, and sales-related milestones.
The structure reflects both the maturity of the asset and the longer-term value Sobi appears to be assigning to a potential future role for pozdeutinurad in the gout treatment landscape.
Sobi, an international biopharmaceutical company that focuses on treatments for rare diseases, framed the acquisition as a meaningful pipeline addition with clear clinical ambition.
The company’s President and CEO said the deal enables Sobi to expand its gout pipeline with a highly differentiated new asset, highlighting pozdeutinurad’s potential to become the therapy of choice for patients living with progressive gout who continue to experience persistent and unresolved symptoms despite first-line therapy.
Conclusion
With the planned acquisition of Arthrosi Therapeutics, Sobi is making a decisive play to strengthen its gout portfolio through the addition of pozdeutinurad (AR882) – a once-daily oral URAT1 inhibitor currently in global phase 3 trials and expected to report results in 2026.
Backed by a $950 million upfront payment and up to $550 million in milestone-linked potential, the deal signals confidence in a treatment designed for patients with progressive and tophaceous gout, particularly those not finding relief with first-line options.
If the upcoming trials deliver on expectations, Sobi’s move could mark a significant step in shaping a new standard for addressing one of the most prevalent and potentially debilitating inflammatory arthritis conditions worldwide.
News Credits: Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
Things you may also like: